Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.
Analysis of rare eye nerve damage reports with semaglutide highlights a safety signal affecting millions of diabetes patients taking this drug.
This systematic review and meta-analysis addresses the emerging safety signal of Non-Arteritic Anterior Ischemic Optic Neuropathy with semaglutide use in T2DM patients, synthesizing available evidence on the magnitude and consistency of this risk. Given semaglutide's enormous and growing patient population, even a modest relative risk increase translates to significant absolute burden, making this pharmacovigilance synthesis clinically important.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- Type 2 diabetes mellitus patients on semaglutide
- Category
- Public Health
- Maturity
- Exploratory
- Journal
- Graefe's Archive for Clinical and Experimental Ophthalmology
Why it surfaced
Meta-analysis on semaglutide-NAION risk is timely and clinically significant given semaglutide's widespread use; pharmacovigilance data has immediate prescribing relevance. Score 6 STANDARD.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.